News | December 25, 2025
Jacobio Pharma partners with AstraZeneca in $2 billion licensing deal for pan-KRAS inhibitor
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
Under the terms of the deal, AstraZeneca gains exclusive rights to JAB-23E73 outside of mainland China
GS-098, a first-in-class, humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor, is designed to rapidly block the pathogenic activity of thyroid-stimulating autoantibodies
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
The new site will produce next-generation synthetic medicine active pharmaceutical ingredients
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
The deal accelerates GE HealthCare’s digital transformation, expanding its reach into outpatient care and enterprise imaging—a $2 billion-plus growth market
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
The non-dilutive financing includes three tranches
The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan
Subscribe To Our Newsletter & Stay Updated
